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Abstract
We report a case of fulminant necrotizing colitis and toxic megaco-
lon in a middle-aged woman, due to infection with Entamoeba his-
tolytica acquired in a non endemic zone of amebiasis, and requiring 
emergent total colectomy due to the occurrence of colon perforation 
and peritonitis. Fulminant colitis is a rare complication of amebia-
sis, which has been only exceptionally reported in the absence of 
a recent travel in endemic areas. In the case presented herein, we 
discuss the possible role of the use of large doses of loperamide, 
as well as that of a co-infection with Norovirus, in triggering the 
fulminant course of the disease.
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Introduction
Amebiasis is a parasitic infection caused by the ingestion of 
the protozoan Entamoeba histolytica via contaminated food 
or water or through fecal-oral contact. Its prevalence is high 
in India, Africa, Mexico, parts of Central and South America, 
and it may occasionally be diagnosed in non endemic areas, 
in migrants and travelers returning from endemic regions. 
Amebiasis is asymptomatic in up to 90% of infected per-
sons, in the others it presents as diarrhea (amebic dysentery) 
or extraintestinal disease (mainly hepatic abscesses) [1, 2]. 
Rarely (< 3% of cases), the disease takes a fulminant course 
characterized by necrotizing colitis that may lead to toxic 
megacolon with a mortality rate of more than 40% [3]. We 
present a patient from a non endemic zone developing such a 
major complication of amebiasis.
 
Case Report
A 45-year-old woman of West African origin was admitted to 
our hospital after a 2 weeks history of progressive abdomi-
nal cramps and bloody diarrhea. She had not travelled to her 
country nor left Western Europe for 5 years, but she reported 
consumption of imported African vegetables (“gumbo”) 
purchased in a local grocery store 3 days before symptom 
onset. Her past history was unremarkable. She was treated 
by her family physician with loperamide and ciprofloxacine 
for 5 days without improvement, and was then admitted to 
a secondary care hospital. A stool specimen was taken and 
showed a positive PCR for Norovirus. The patient was treat-
ed by supportive care, but after 3 days, she was transferred 
to our tertiary care hospital due to progressive hypotension 
and increasing abdominal pain. On admission, the patient 
was in a poor general condition, her core temperature was 
38.3 °C, arterial blood pressure was 100/50 mmHg and heart 
rate was 100 bpm. The abdomen was dilated, with diffuse 
tenderness and signs of peritonitis. Laboratory examination 
showed normal leukocyte count at 6.2 G/L, a C reactive 
protein at 222 mg/L, signs of acute renal failure (creatinine 
162 μmol/L) and disseminated intravascular coagulation. 
HIV serology was negative. An abdominal CT scan revealed 
large bowel dilatation (8 cm) with a thickened colonic wall 
and a peri-colic fat infiltration (Fig. 1A). While the patient 
was prepared for emergency surgery, she developed cardiac 
arrest due to ventricular fibrillation requiring cardio-pulmo-
nary resuscitation that was successful after 10 minutes. An 
emergent total colectomy was then performed for necrotic 
pancolitis with perforation (Fig. 1B) and the patient postop-
eratively was admitted to the intensive care unit (ICU). His-
topathological examination revealed extensive large bowel 
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necrosis with multiple deep ulcers, massive infiltration with 
Entamoeba trophozoites and signs of hemophagocytosis 
(Fig. 1C). The patient was successfully treated with a ten 
day course of metronidazole followed by 7 days of paromo-
mycin for eradication of the documented intraluminal cysts. 
She was transferred to the general ward after a 3 weeks’ stay 
at the ICU and then to a neurological rehabilitation unit for 
the management of moderate post-anoxic encephalopathy.
Discussion
  
Fulminant amebic colitis is an uncommon and severe com-
plication of infection with E. histolytica. Toxic dilatation is 
rare and portends a poor prognosis. The diagnosis is often 
delayed and is generally made histologically in operative 
or postmortem specimens. Risk factors for invasive disease 
include the virulence of the strain of E. histolytica, as well 
as host factors including genetic susceptibility, young age, 
pregnancy and impaired immunity (for example. due to 
treatment with corticosteroids, malignancy, malnutrition, 
alcoholism, and HIV infection) [4-6]. The patient under dis-
cussion developed fulminant colitis within a non endemic 
region, a feature which has only been rarely reported in the 
absence of recent travelling [7]. Considering her African 
origin, she could have been infected prior to her arrival in 
Europe, which would be consistent with a long-lasting (more 
than 5 years) carrier state. An alternative possibility would 
be a recent contamination due to the ingestion of vegetables 
obtained in a local African grocery. In such a scenario, the 
vegetable might have either carried amebic cysts imported 
from Africa (given their ability to survive several weeks in 
soil or water) or have been locally contaminated by the Af-
rican food seller. In either case, two potentially precipitating 
factors may have been the co-infection with Norovirus and 
treatment with large amounts of loperamide. Considering the 
former, it is noteworthy that there is no previous report of 
co-infection with Norovirus and E. histolytica. With respect 
to the latter, several reports have suggested that loperamide 
may promote toxic intestinal dilatation in case of gut infec-
tions with invasive or toxin-producing organisms [8]. In-
deed, loperamide inhibits intestinal smooth muscle function, 
thereby prolonging the contact of invasive organisms (such 
as E. histolytica) with the mucosa. It is also particularly note-
worthy that the patient developed an extremely severe form 
of the disease in the absence of impaired immune status, 
which further supports the potential role played by the co-
infection with Norovirus and the treatment with loperamide.
We conclude that amebiasis may occur in non endemic 
zones and may be complicated by acute fulminant necrotiz-
ing colitis and toxic megacolon, requiring emergency resec-
tion surgery combined with antiamebic treatment. The use 
of loperamide may represent a major precipitating factor for 
such a complication, and should be avoided when signs of 
mucosal involvement, such as rectal bleeding and fever, are 
present during the course of gastroenteritis. This is the first 
case report of co-infection with Norovirus and E. histolytica, 
which may have contributed to the particularly severe clini-
cal course.
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Figure 1. Acute necrotizing colitis due to invasive amebiasis. 
A. Marked dilatation of the colon lumen with thickened co-
lonic wall, particularly at the level of the caecum (arrow). B. 
Colectomy specimen showing diffuse necrosis of the colon. 
C. Histopathological study of the colon, identifying numerous 
amebic trophozoites (arrows), with overt pictures of hemo-
phagocytosis (arrowhead).
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